phase 1 Search Results


gx-188e vaccine  (Genexine Inc)
90
Genexine Inc gx-188e vaccine
Gx 188e Vaccine, supplied by Genexine Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phase+1/pmc04220493-220-15-2?v=Genexine+Inc
Average 90 stars, based on 1 article reviews
gx-188e vaccine - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
phase 1 trial  (Stemcentrx)
90
Stemcentrx phase 1 trial
Phase 1 Trial, supplied by Stemcentrx, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phase+1/pm27404868-16-5-0?v=Stemcentrx
Average 90 stars, based on 1 article reviews
phase 1 trial - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
joint movement phase 1  (CH Instruments)
90
CH Instruments joint movement phase 1
Joint Movement Phase 1, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phase+1/pmc11000395-4-0-4?v=CH+Instruments
Average 90 stars, based on 1 article reviews
joint movement phase 1 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
phase 1/2 a protocol  (Clinilabs)
90
Clinilabs phase 1/2 a protocol
Phase 1/2 A Protocol, supplied by Clinilabs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phase+1/pm36456694-2065-1-12?v=Clinilabs
Average 90 stars, based on 1 article reviews
phase 1/2 a protocol - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
phase 1 clinical trial nct01375842  (Genentech inc)
90
Genentech inc phase 1 clinical trial nct01375842
Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. For the phase 1 clinical trial <t>NCT01375842</t> the study sponsor (Genentech Inc) provided data (unpublished). Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; and RE MODEL, random effects model.
Phase 1 Clinical Trial Nct01375842, supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phase+1/pmc05838579-109-25-36?v=Genentech+inc
Average 90 stars, based on 1 article reviews
phase 1 clinical trial nct01375842 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
phase 1/2 randomized trial  (Accelagen inc)
90
Accelagen inc phase 1/2 randomized trial
Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. For the phase 1 clinical trial <t>NCT01375842</t> the study sponsor (Genentech Inc) provided data (unpublished). Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; and RE MODEL, random effects model.
Phase 1/2 Randomized Trial, supplied by Accelagen inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phase+1/pmc08216129-117-2-10?v=Accelagen+inc
Average 90 stars, based on 1 article reviews
phase 1/2 randomized trial - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
snps from the 1000 genomes phase 1 high confidence dataset  (Broad Institute Inc)
90
Broad Institute Inc snps from the 1000 genomes phase 1 high confidence dataset
Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. For the phase 1 clinical trial <t>NCT01375842</t> the study sponsor (Genentech Inc) provided data (unpublished). Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; and RE MODEL, random effects model.
Snps From The 1000 Genomes Phase 1 High Confidence Dataset, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phase+1/pm36882706-97-0-14?v=Broad+Institute+Inc
Average 90 stars, based on 1 article reviews
snps from the 1000 genomes phase 1 high confidence dataset - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
phase 1 powders  (Qinetiq Ltd)
90
Qinetiq Ltd phase 1 powders
Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. For the phase 1 clinical trial <t>NCT01375842</t> the study sponsor (Genentech Inc) provided data (unpublished). Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; and RE MODEL, random effects model.
Phase 1 Powders, supplied by Qinetiq Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phase+1/pmc02685765-263-11-4?v=Qinetiq+Ltd
Average 90 stars, based on 1 article reviews
phase 1 powders - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
phase 1 and 2 trials  (Regeneron inc)
90
Regeneron inc phase 1 and 2 trials
Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. For the phase 1 clinical trial <t>NCT01375842</t> the study sponsor (Genentech Inc) provided data (unpublished). Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; and RE MODEL, random effects model.
Phase 1 And 2 Trials, supplied by Regeneron inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phase+1/pm22481387-32-23-22?v=Regeneron+inc
Average 90 stars, based on 1 article reviews
phase 1 and 2 trials - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
phase 1 inhibitors  (Achillion inc)
90
Achillion inc phase 1 inhibitors
Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. For the phase 1 clinical trial <t>NCT01375842</t> the study sponsor (Genentech Inc) provided data (unpublished). Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; and RE MODEL, random effects model.
Phase 1 Inhibitors, supplied by Achillion inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phase+1/pm36770965-323-15-25?v=Achillion+inc
Average 90 stars, based on 1 article reviews
phase 1 inhibitors - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
phase 1 nal report  (Air Products and Chemicals)
90
Air Products and Chemicals phase 1 nal report
Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. For the phase 1 clinical trial <t>NCT01375842</t> the study sponsor (Genentech Inc) provided data (unpublished). Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; and RE MODEL, random effects model.
Phase 1 Nal Report, supplied by Air Products and Chemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phase+1/10__1039_slash_c9se00619b-446-19-26?v=Air+Products+and+Chemicals
Average 90 stars, based on 1 article reviews
phase 1 nal report - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
anti-salmonella poly-h phase 1 2  (sifin diagnostics)
90
sifin diagnostics anti-salmonella poly-h phase 1 2
Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. For the phase 1 clinical trial <t>NCT01375842</t> the study sponsor (Genentech Inc) provided data (unpublished). Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; and RE MODEL, random effects model.
Anti Salmonella Poly H Phase 1 2, supplied by sifin diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phase+1/10__1093_slash_jaoac_slash_92__6__1885-53-3-8?v=sifin+diagnostics
Average 90 stars, based on 1 article reviews
anti-salmonella poly-h phase 1 2 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. For the phase 1 clinical trial NCT01375842 the study sponsor (Genentech Inc) provided data (unpublished). Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; and RE MODEL, random effects model.

Journal: JAMA Oncology

Article Title: Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens

doi: 10.1001/jamaoncol.2017.3064

Figure Lengend Snippet: Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. For the phase 1 clinical trial NCT01375842 the study sponsor (Genentech Inc) provided data (unpublished). Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; and RE MODEL, random effects model.

Article Snippet: Given that this agent was recently approved, and there are few clinical trials available, we used unpublished data on phase 1 clinical trial ( {"type":"clinical-trial","attrs":{"text":"NCT01375842","term_id":"NCT01375842"}} NCT01375842 ) that was provided to us by the study sponsor (Genentech Inc).

Techniques:

Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. For the phase 1 clinical trial NCT01375842 the study sponsor (Genentech Inc) provided data (unpublished). Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; and RE MODEL, random effects model.

Journal: JAMA Oncology

Article Title: Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens

doi: 10.1001/jamaoncol.2017.3064

Figure Lengend Snippet: Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. For the phase 1 clinical trial NCT01375842 the study sponsor (Genentech Inc) provided data (unpublished). Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; and RE MODEL, random effects model.

Article Snippet: Given that this agent was recently approved, and there are few clinical trials available, we used unpublished data on phase 1 clinical trial ( {"type":"clinical-trial","attrs":{"text":"NCT01375842","term_id":"NCT01375842"}} NCT01375842 ) that was provided to us by the study sponsor (Genentech Inc).

Techniques: